Guildford, UK, 14 December 2006: ReNeuron Group plc (LSE: RENE) today announces that the Company has raised approximately £1.9 million from the proceeds of the exercise of Warrants to purchase Ordinary Shares in the Company at a price of 10 pence per share.
ReNeuron files IND application to commence human clinical studies with ReN001 stem cell therapy for stroke
First such application to use neural (brain) stem cells to treat a major neurological condition
Guildford, UK, 6 December 2006:
ReNeuron Group plc (LSE: RENE.L) today announces the filing of its first Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to commence initial clinical studies in the US with ReN001, its stem cell therapy for stroke.
Guildford, UK, 30 November 2006: ReNeuron Group plc (LSE: RENE.L) and CellSeed Inc., a privately owned tissue engineering company based in Tokyo, Japan, today announce the signing of a collaboration agreement to develop novel, patented liver cell culture systems for drug safety screening in the pharmaceutical industry.
Guildford, UK, 22 November 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it will report its interim results for the six months ended 30 September 2006 on Wednesday 6 December 2006.
Guildford,UK, 20 November 2006: ReNeuron Group plc (LSE:RENE.L) and Millipore Corporation (NYSE:MIL), announce the market launch of ReNeuron’s patented ReNcellTM neural stem cell lines for non-therapeutic applications. These products are the only immortalised human somatic neural stem cell lines on the market today.
Guildford, UK, 15 November 2006: ReNeuron Group plc (LSE: RENE) gives notice reminding Warrant holders that, in accordance with the terms of the Warrant Instrument dated 4 August 2005 (as amended), the exercise period of the Warrants shall end on 12 December 2006.
ReNeuron to Present at American Neurological Association Conference
Results to Form Part of Data Package to the US FDA In Support of Application to Commence Clinical Studies with ReN001-
Guildford, UK, 21 September 2006: ReNeuron Group plc (LSE: RENE) today announces that all resolutions put to Warrant holders at a meeting of Warrant holders held on 21 September 2006 (the Meeting) were passed.
Guildford, UK, 21 September 2006: ReNeuron Group plc (LSE: RENE) today announces that all resolutions put to its Shareholders at its 2006 Annual General Meeting (the AGM) were passed.
ReNeuron Group plc (LSE: RENE) today announces that it has appointed Professor Douglas Kondziolka MD, MSc, FRCS, FACS as Principal Investigator for the Phase l clinical study with its ReN001 stem cell therapy for disabled stroke patients. This appointment represents a further step in ReNeuron’s preparations for the clinical phase of its development programme for ReN001.
